Roche says data in hepatitis treatment encouraging
ZURICH (Reuters) - Swiss drugmaker Roche said on Thursday initial data on a protease inhibitor, danoprevir, is encouraging against Hepatitis C.
"The high sustained viral response rates and encouraging safety data show danoprevir is potent and well-tolerated," Roche development head Hal Barron said in a statement.
"Roche's HCV portfolio includes multiple investigational drugs with different modes of action, allowing us to develop tailored treatments that aim to address the future needs of patients with chronic hepatitis C," Barron said.
(Reporting By Katharina Bart)
- Tweet this
- Share this
- Digg this
- São Paulo running out of water as rain-making Amazon vanishes
- Maker of U.S. highway guardrails stops shipments over safety concerns
- Woman isolated in NJ under Ebola rules tests negative
- Iran hangs woman convicted of killing alleged rapist
- Reuters Poll - India's growth pace to pick up as reforms draw investment
New York and New Jersey will automatically quarantine medical workers returning from Ebola-hit West African countries and the U.S. government is considering the same step after a doctor who treated patients in Guinea came back infected, officials said. Full Article | Slideshow